Development of a humanised antibody to MIC-1/GDF15 for therapy of anorexia/cachexia of cancer

开发用于治疗癌症厌食症/恶病质的 MIC-1/GDF15 人源化抗体

• 批准号: nhmrc : 1017594
• 负责人: A/Pr Daniel Christ
• 金额: $ 39.16万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-humanised-antibody-anorexiacachexia-cancer/109880
• 关键词: Development; humanised; antibody; MIC; GDF15

Severe starvation and weight loss (cachexia) is a complication that affects about one quarter of cancer patients. In many this is due to the cancer producing a powerfula appetite suppressive protein called MIC-1/GDF15. This weight loss can be prevented by blocking the protein with an antibody drug. We have already shown that we can treat mice in this way by using a mouse antibody. We now aim to engineer these antibodies by making them more human-like. This will allow us to treat weight loss in human cancer patients.

严重饥饿和体重减轻(恶病质)是一种并发症，影响大约四分之一的癌症患者。在许多情况下，这是由于癌症产生了一种名为MIC-1/GDF15的强大的食欲抑制蛋白。这种体重减轻可以通过用抗体药物阻断蛋白质来预防。我们已经证明，我们可以通过使用小鼠抗体以这种方式对待小鼠。我们现在的目标是通过使这些抗体更像人类来设计这些抗体。这将使我们能够治疗人类癌症患者的体重减轻。